Login
Home / ALA.AX : ASX
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Arovella Therapeutics Limited

AUD 0.06 -$0.03 (-36.56%)
ASX · 16 Sep 2026 06:10 UTC
Previous Close
AUD 0.06
Day Range
AUD 0.06AUD 0.06
Year Range
AUD 0.06AUD 0.12
Market Cap
71.32M
AVG Volume
678.49K
Trailing/Forward PE
-10.17/-
PEG ratio
-0.26
Dividend Yield
-
Next Earnings Date
2027-02-25
Primary Exchange
Australian Securities ExchangeAU
Revenue (AUD)
-4M-2M02M4M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Net Income (AUD)
-8M-6M-4M-2M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Operating Income (AUD)
-15M-10M-5M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
EBITDA (AUD)
-10M-7.5M-5M-2.5M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Cash Flows (AUD)
-6M-4M-2M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
EPS (AUD)
-0.01-0.01-0-0022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Expenses (AUD)
-2M02M4M6MR&DSG&ACapex22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Cash & Debt (AUD)
-10M010M20M30MCashLong Term DebtShort Term Debt22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Debt ratios
00.20.40.60.822 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Margins
-20000%-15000%-10000%-5000%0%5000%21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
Return on Capital
-200%-150%-100%-50%0%22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Shares Outstanding
0500M1B1.5B22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Book Value Per Share (AUD)
00.010.010.010.0222 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Total Assets (AUD)
010M20M30M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Free Cash Flow Yield
-20%-15%-10%-5%med -14.57%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
0200400600800med 484.06Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
05101520med 5.56Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Arovella Therapeutics Limited
ALA.AX
Stockpicker

Video analysis: ALA.AX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ALA.AX

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

gurufocus.com · 13 Jul 2026

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.